Radiation and immunotherapy for advanced multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or didn't respond to at least one prior treatment, including certain types of drugs (IMiDs, proteasome inhibitors, or anti-CD38 antibodies).
- Your cancer has spread to soft tissues (extramedullary disease) or outside the bone (paramedullary disease), seen on a scan like PET/CT or MRI.
- You have at least one spot of this spread that hasn't been treated with radiation before and can be safely treated with radiation.
- Your blood counts and organ function meet safe levels: hemoglobin at least 7 g/dL, platelets at least 50K, neutropils at least 0.75K, and adequate kidney and liver function.
- You are physically active enough to be up and about more than half the day (ECOG performance status 0-2), unless limitations are due to myeloma pain.
- If you could become pregnant, you agree to use effective birth control and have negative pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.